Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma.
BACKGROUND
Hypoxia is associated with increased resistance to chemo- and radiation-therapy. Hyperoxic treatment (hyperbaric oxygen) has previously been shown to potentiate the effect of some forms of chemotherapy, and this has been ascribed to enhanced cytotoxicity or neovascularisation. The aim of this study was to elucidate whether hyperoxia also enhances any actual uptake of 5FU (5-fluorouracil) into the tumor tissue and if this can be explained by changes in the interstitium and extracellular matrix.


METHODS
One group of tumor bearing rats was exposed to repeated hyperbaric oxygen (HBO) treatment (2 bar, pO(2)= 2 bar, 4 exposures à 90 min), whereas one group was exposed to one single identical HBO treatment. Animals housed under normal atmosphere (1 bar, pO(2) = 0.2 bar) served as controls. Three doses of 5FU were tested for dose response. Uptake of [3H]-5FU in the tumor was assessed, with special reference to factors that might have contributed, such as interstitial fluid pressure (Pif), collagen content, oxygen stress (measured as malondialdehyd levels), lymphatics and transcapillary transport in the tumors.


RESULTS
The uptake of the cytostatic agent increases immediately after a single HBO treatment (more than 50%), but not 24 hours after the last repeated HBO treatment. Thus, the uptake is most likely related to the transient increase in oxygenation in the tumor tissue. Factors like tumor Pif and collagen content, which decreased significantly in the tumor interstitium after repeated HBO treatment, was without effect on the drug uptake.


CONCLUSIONS
We showed that hyperoxia increases the uptake of [3H]-5FU in DMBA-induced mammary tumors per se, independently of changes in Pif, oxygen stress, collagen fibril density, or transendothelial transport alone. The mechanism by which such an uptake occur is still not elucidated, but it is clearly stimulated by elevated pO(2).
Moen
Ingrid
I
Department of Biomedicine, University of Bergen, Bergen, Norway. ingrid.moen@biomed.uib.no
Tronstad
Karl J
KJ
Kolmannskog
Odd
O
Salvesen
Gerd S
GS
Reed
Rolf K
RK
Stuhr
Linda E B
LE
D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000493:pharmacokinetics; D001810:Blood Volume / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D045604:Extracellular Fluid / Q000502:physiology*; D005260:Female; D005472:Fluorouracil / Q000493:pharmacokinetics*; D006931:Hyperbaric Oxygenation; D018496:Hyperoxia / Q000378:metabolism / Q000503:physiopathology*; D008196:Lymph / Q000502:physiology; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D009997:Osmotic Pressure / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism; D017154:Stromal Cells / Q000473:pathology
D000964:Antimetabolites, Antineoplastic; D017382:Reactive Oxygen Species; D005472:Fluorouracil